SmithKline Beecham

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

3 days ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment

iTeos to Shut Down Operations After TIGIT Therapy Setback

2 weeks ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges

2 weeks ago talkbio0Tagged Antibiotics, Clinical Trials, Complicated, HBr, PIVOT-PO trial, SmithKline Beecham, Spero Therapeutics, Stock Surge, Submission, United States Food and Drug Administration, Urinary tract infection

GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission

GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena

4 weeks ago talkbio0Tagged Analog, Boston Pharmaceuticals, drug acquisition, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, Phase III, SLC17A5 gene, SmithKline Beecham

GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

4 weeks ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

2 months ago talkbio0Tagged Abetalipoproteinemia, Bio, Blood - brain barrier anatomy, Grabody-B, IGF1R gene, Neurodegenerative Disorders, SmithKline Beecham

Abetalipoproteinemia, SmithKline Beecham, Bio, Grabody-B, Neurodegenerative Disorders, Blood – brain barrier anatomy, IGF1R gene

FDA Approves Blujepa: First New Oral Antibiotic for Uncomplicated UTIs in Nearly 30 Years

3 months ago talkbio0Tagged Approved, Blujepa, first-in-class antibiotic, gepotidacin, SmithKline Beecham, United States Food and Drug Administration, Urinary tract infection, uUTIs

Gepotidacin, Blujepa, GSK, uncomplicated urinary tract infections (uUTIs), FDA approval, first-in-class antibiotic

GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction

3 months ago talkbio0Tagged Dementia Research Institute, Health Data Research UK, Nance-Horan syndrome, Presenile dementia, research study, Shingrix, SmithKline Beecham

GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment

GSK’s Penmenvy Approved: New 5-in-1 Meningococcal Vaccine Enters U.S. Market

4 months ago talkbio0Tagged Approved, Invasive meningococcal disease, MenABCWY, Meningococcal vaccine, Penmenvy, SmithKline Beecham, United States Food and Drug Administration, Vaccines

Penmenvy, GSK, meningococcal vaccine, FDA approval, 5-in-1 vaccine, MenABCWY, invasive meningococcal disease (IMD)

GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market

4 months ago talkbio0Tagged Adolescent (age group), Approved, Invasive meningococcal disease, Meningococcal vaccine, Penmenvy, Pfizer, SmithKline Beecham, United States Food and Drug Administration, Vaccines, Young Adult

Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults